$NVAX #nvax $24 target by 12/9/2024
Novavax, 
NVAX phase 3 trial begins on 12/9/2024. ctv.veeva.com/study/phase-3-study-of-the-safety-and-immunogenicity-of-covid-19-and-influenza-combination-vaccine A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
NVAX phase 3 trial begins on 12/9/2024. ctv.veeva.com/study/phase-3-study-of-the-safety-and-immunogenicity-of-covid-19-and-influenza-combination-vaccine A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。